Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924693 | 0.78 | NOS3 (0.35) | F2SLC6A4S1PR4CYP1A2CYP2D6 | |
| SCHEMBL924336 | 0.76 | F2 (0.32) | F2NPSR1MAPK1MAPT | |
| SCHEMBL25216222 | 0.67 | HTR2A (0.35) | KCNH2NPSR1HTR2ASLC6A4 | |
| SCHEMBL6822871 | 0.66 | IDO1 (0.32) | HTR2ASLC6A4S1PR4MAPT | |
| SCHEMBL6818762 | 0.66 | NOS3 (0.40) | HTR2ASLC6A4CYP1A2CYP2D6MAPT | |
| SCHEMBL5605178 | 0.65 | IDO1 (0.53) | MAPK1CYP1A2CYP2D6PKML3MBTL1 | |
| SCHEMBL6816069 | 0.64 | ENPP2 (0.35) | HTR2ASLC6A4CYP1A2CYP2D6PTGER1 | |
| SCHEMBL16497034 | 0.63 | PYCR1 (0.43) | MAPK1SLC6A4CYP1A2CYP2D6MAPT | |
| SCHEMBL624403 | 0.63 | TSHR (0.47) | NPSR1MAPK1HTR2ASLC6A4CYP1A2 | |
| SCHEMBL4284080 | 0.62 | SLC6A4 (0.48) | KCNH2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009399-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2231677-A2 | TRISUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074674-A2 | TRISUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009399-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | F2 143/4885KCNH2 84/4885NPSR1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.